SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Anika Therapeutics, Inc. – ‘10-K’ for 12/31/20 – ‘XML’

On:  Friday, 3/5/21, at 5:18pm ET   ·   For:  12/31/20   ·   Accession #:  1171843-21-1573   ·   File #:  1-14027

Previous ‘10-K’:  ‘10-K’ on 3/6/20 for 12/31/19   ·   Next:  ‘10-K/A’ on 4/26/21 for 12/31/20   ·   Latest:  ‘10-K/A’ on 4/26/24 for 12/31/23   ·   37 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/05/21  Anika Therapeutics, Inc.          10-K       12/31/20  105:11M                                    Globenewswire Inc./FA

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.34M 
 6: EX-10.13D   Material Contract                                   HTML     94K 
 7: EX-10.13E   Material Contract                                   HTML     93K 
 8: EX-10.13G   Material Contract                                   HTML     85K 
 9: EX-10.13H   Material Contract                                   HTML     93K 
 2: EX-23.1     Consent of Expert or Counsel                        HTML     29K 
 3: EX-31.1     Certification -- §302 - SOA'02                      HTML     35K 
 4: EX-31.2     Certification -- §302 - SOA'02                      HTML     36K 
 5: EX-32.1     Certification -- §906 - SOA'02                      HTML     30K 
16: R1          Document And Entity Information                     HTML     89K 
17: R2          Consolidated Balance Sheets                         HTML    112K 
18: R3          Consolidated Balance Sheets (Parentheticals)        HTML     47K 
19: R4          Consolidated Statements of Operations and           HTML    108K 
                Comprehensive Income (Loss)                                      
20: R5          Consolidated Statements of Stockholders' Equity     HTML     85K 
21: R6          Consolidated Statements of Cash Flows               HTML    152K 
22: R7          Note 1 - Nature of Business                         HTML     35K 
23: R8          Note 2 - Summary of Significant Accounting          HTML    118K 
                Policies                                                         
24: R9          Note 3 - Business Combinations                      HTML    100K 
25: R10         Note 4 - Fair Value Measurements                    HTML     90K 
26: R11         Note 5 - Inventories                                HTML     44K 
27: R12         Note 6 - Property and Equipment                     HTML     44K 
28: R13         Note 7 - Acquired Intangible Assets, Net            HTML     85K 
29: R14         Note 8 - Goodwill                                   HTML     47K 
30: R15         Note 9 - Leases                                     HTML     79K 
31: R16         Note 10 - Accrued Expenses                          HTML     43K 
32: R17         Note 11 - Revolving Credit Agreement                HTML     35K 
33: R18         Note 12 - Commitments and Contingencies             HTML     34K 
34: R19         Note 13 - Revenue by Product Group, by Significant  HTML     87K 
                Customer and by Geographic Location; Geographic                  
                Information                                                      
35: R20         Note 14 - Equity Incentive Plan                     HTML    108K 
36: R21         Note 15 - Employee Benefit Plan                     HTML     33K 
37: R22         Note 16 - Accelerated Share Repurchases             HTML     36K 
38: R23         Note 17 - Income Taxes                              HTML    120K 
39: R24         Note 18 - Earnings Per Share ("Eps")                HTML     43K 
40: R25         Note 19 - Quarterly Financial Data (Unaudited)      HTML     67K 
41: R26         Significant Accounting Policies (Policies)          HTML    171K 
42: R27         Note 2 - Summary of Significant Accounting          HTML     52K 
                Policies (Tables)                                                
43: R28         Note 3 - Business Combinations (Tables)             HTML     81K 
44: R29         Note 4 - Fair Value Measurements (Tables)           HTML     85K 
45: R30         Note 5 - Inventories (Tables)                       HTML     42K 
46: R31         Note 6 - Property and Equipment (Tables)            HTML     42K 
47: R32         Note 7 - Acquired Intangible Assets, Net (Tables)   HTML     79K 
48: R33         Note 8 - Goodwill (Tables)                          HTML     39K 
49: R34         Note 9 - Leases (Tables)                            HTML     76K 
50: R35         Note 10 - Accrued Expenses (Tables)                 HTML     41K 
51: R36         Note 13 - Revenue by Product Group, by Significant  HTML     86K 
                Customer and by Geographic Location; Geographic                  
                Information (Tables)                                             
52: R37         Note 14 - Equity Incentive Plan (Tables)            HTML    102K 
53: R38         Note 17 - Income Taxes (Tables)                     HTML    115K 
54: R39         Note 18 - Earnings Per Share ("Eps") (Tables)       HTML     40K 
55: R40         Note 19 - Quarterly Financial Data (Unaudited)      HTML     65K 
                (Tables)                                                         
56: R41         Note 2 - Summary of Significant Accounting          HTML     72K 
                Policies (Details Textual)                                       
57: R42         Note 2 - Summary of Significant Accounting          HTML     39K 
                Policies - Allowance for Doubtful Accounts                       
                (Details)                                                        
58: R43         Note 2 - Summary of Significant Accounting          HTML     39K 
                Policies - Estimated Useful Lives of Property and                
                Equipment (Details)                                              
59: R44         Note 3 - Business Combinations (Details Textual)    HTML     74K 
60: R45         Note 3 - Business Combinations - Consideration      HTML     41K 
                Transferred (Details)                                            
61: R46         Note 3 - Business Combinations - Fair Value of Net  HTML     74K 
                Assets Acquired (Details)                                        
62: R47         Note 3 - Business Combinations - Intangible Assets  HTML     43K 
                Acquired (Details)                                               
63: R48         Note 3 - Business Combinations - Pro Forma          HTML     32K 
                Information (Details)                                            
64: R49         Note 4 - Fair Value Measurements (Details Textual)  HTML     68K 
65: R50         Note 4 - Fair Value Measurements - Fair Value of    HTML     62K 
                Financial Instruments (Details)                                  
66: R51         Note 4 - Fair Value Measurements - Contingent       HTML     38K 
                Consideration (Details)                                          
67: R52         Note 5 - Inventories (Details Textual)              HTML     34K 
68: R53         Note 5 - Inventories - Summary of Inventories       HTML     41K 
                (Details)                                                        
69: R54         Note 6 - Property and Equipment (Details Textual)   HTML     30K 
70: R55         Note 6 - Property and Equipment - Property and      HTML     43K 
                Equipment at Cost (Details)                                      
71: R56         Note 7 - Acquired Intangible Assets, Net (Details   HTML     50K 
                Textual)                                                         
72: R57         Note 7 - Acquired Intangible Assets, Net - Summary  HTML     63K 
                of Intangible Assets (Details)                                   
73: R58         Note 8 - Goodwill (Details Textual)                 HTML     32K 
74: R59         Note 8 - Goodwill - Changes in the Carrying Value   HTML     38K 
                of Goodwill (Details)                                            
75: R60         Note 9 - Leases (Details Textual)                   HTML     32K 
76: R61         Note 9 - Leases - Lease Expense and Other           HTML     58K 
                Information (Details)                                            
77: R62         Note 9 - Leases - Future Minimum Rental Payments    HTML     95K 
                for Operating Leases (Details)                                   
78: R63         Note 10 - Accrued Expenses - Summary of Accrued     HTML     45K 
                Expenses (Details)                                               
79: R64         Note 11 - Revolving Credit Agreement (Details       HTML     63K 
                Textual)                                                         
80: R65         Note 12 - Commitments and Contingencies (Details    HTML     30K 
                Textual)                                                         
81: R66         Note 13 - Revenue by Product Group, by Significant  HTML     35K 
                Customer and by Geographic Location; Geographic                  
                Information (Details Textual)                                    
82: R67         Note 13 - Revenue by Product Group, by Significant  HTML     50K 
                Customer and by Geographic Location; Geographic                  
                Information - Product Revenue by Product Group                   
                (Details)                                                        
83: R68         Note 13 - Revenue by Product Group, by Significant  HTML     47K 
                Customer and by Geographic Location; Geographic                  
                Information - Total Revenue by Geographic Location               
                (Details)                                                        
84: R69         Note 13 - Revenue by Product Group, by Significant  HTML     34K 
                Customer and by Geographic Location; Geographic                  
                Information - Net Tangible Long-lived Assets by                  
                Principal Geographic Areas (Details)                             
85: R70         Note 14 - Equity Incentive Plan (Details Textual)   HTML    131K 
86: R71         Note 14 - Equity Incentive Plan - Granted and       HTML     48K 
                Exercised Stock-based Compensation Awards                        
                (Details)                                                        
87: R72         Note 14 - Equity Incentive Plan - Stock Options     HTML     50K 
                and SAR's Activity (Details)                                     
88: R73         Note 14 - Equity Incentive Plan - Summary of        HTML     41K 
                Exercisable Options and SAR's (Details)                          
89: R74         Note 14 - Equity Incentive Plan - Restricted Stock  HTML     50K 
                Activity (Details)                                               
90: R75         Note 14 - Equity Incentive Plan - Assumptions Used  HTML     42K 
                to Estimate Fair Value of Stock Options and Stock                
                Appreciation Rights (Details)                                    
91: R76         Note 14 - Equity Incentive Plan - Total             HTML     36K 
                Stock-based Compensation Expense (Details)                       
92: R77         Note 15 - Employee Benefit Plan (Details Textual)   HTML     33K 
93: R78         Note 16 - Accelerated Share Repurchases (Details    HTML     72K 
                Textual)                                                         
94: R79         Note 17 - Income Taxes (Details Textual)            HTML     59K 
95: R80         Note 17 - Income Taxes - Components of Income       HTML     63K 
                Before Taxes and Provision for (Benefit from)                    
                Income Taxes (Details)                                           
96: R81         Note 17 - Income Taxes - Significant Components of  HTML     62K 
                Company's Deferred Tax Assets and Liabilities                    
                (Details)                                                        
97: R82         Note 17 - Income Taxes - Reconciliation Between     HTML     52K 
                U.S. Federal Statutory Rate and Effective Rate                   
                (Details)                                                        
98: R83         Note 18 - Earnings Per Share ("Eps") (Details       HTML     34K 
                Textual)                                                         
99: R84         Note 18 - Earnings Per Share ("EPS") - Basic and    HTML     38K 
                Diluted Earnings Per Share (Details)                             
100: R85         Note 19 - Quarterly Financial Data (Unaudited)      HTML     34K  
                (Details Textual)                                                
101: R86         Note 19 - Quarterly Financial Data (Unaudited) -    HTML     67K  
                Quarterly Financial Data (Unaudited) (Details)                   
103: XML         IDEA XML File -- Filing Summary                      XML    199K  
15: XML         XBRL Instance -- anik20201231_10k_htm                XML   2.55M 
102: EXCEL       IDEA Workbook of Financial Reports                  XLSX    118K  
11: EX-101.CAL  XBRL Calculations -- anik-20201231_cal               XML    186K 
12: EX-101.DEF  XBRL Definitions -- anik-20201231_def                XML   1.68M 
13: EX-101.LAB  XBRL Labels -- anik-20201231_lab                     XML   1.36M 
14: EX-101.PRE  XBRL Presentations -- anik-20201231_pre              XML   1.72M 
10: EX-101.SCH  XBRL Schema -- anik-20201231                         XSD    250K 
104: JSON        XBRL Instance as JSON Data -- MetaLinks              456±   766K  
105: ZIP         XBRL Zipped Folder -- 0001171843-21-001573-xbrl      Zip    374K

‘XML’   —   IDEA XML File — Filing Summary

This Document is an IDEA XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<FilingSummary>
<Version> 3.20.4 </Version>
<ProcessingTime/>
<ReportFormat> html </ReportFormat>
<ContextCount> 294 </ContextCount>
<ElementCount> 506 </ElementCount>
<EntityCount> 1 </EntityCount>
<FootnotesReported> true </FootnotesReported>
<SegmentCount> 87 </SegmentCount>
<ScenarioCount> 0 </ScenarioCount>
<TuplesReported> false </TuplesReported>
<UnitCount> 6 </UnitCount>
<MyReports>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R1.htm </HtmlFileName>
<LongName> 000 - Document - Document And Entity Information </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-document-and-entity-information </Role>
<ShortName> Document And Entity Information </ShortName>
<MenuCategory> Cover </MenuCategory>
<Position> 1 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R2.htm </HtmlFileName>
<LongName> 001 - Statement - Consolidated Balance Sheets </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-consolidated-balance-sheets </Role>
<ShortName> Consolidated Balance Sheets </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 2 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R3.htm </HtmlFileName>
<LongName> 002 - Statement - Consolidated Balance Sheets (Parentheticals) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-consolidated-balance-sheets-parentheticals </Role>
<ShortName> Consolidated Balance Sheets (Parentheticals) </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 3 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R4.htm </HtmlFileName>
<LongName> 003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss </Role>
<ShortName> Consolidated Statements of Operations and Comprehensive Income (Loss) </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 4 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R5.htm </HtmlFileName>
<LongName> 004 - Statement - Consolidated Statements of Stockholders' Equity </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-consolidated-statements-of-stockholders-equity </Role>
<ShortName> Consolidated Statements of Stockholders' Equity </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 5 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R6.htm </HtmlFileName>
<LongName> 005 - Statement - Consolidated Statements of Cash Flows </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-consolidated-statements-of-cash-flows </Role>
<ShortName> Consolidated Statements of Cash Flows </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 6 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R7.htm </HtmlFileName>
<LongName> 006 - Disclosure - Note 1 - Nature of Business </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-1-nature-of-business </Role>
<ShortName> Note 1 - Nature of Business </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 7 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R8.htm </HtmlFileName>
<LongName> 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-2-summary-of-significant-accounting-policies </Role>
<ShortName> Note 2 - Summary of Significant Accounting Policies </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 8 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R9.htm </HtmlFileName>
<LongName> 008 - Disclosure - Note 3 - Business Combinations </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-3-business-combinations </Role>
<ShortName> Note 3 - Business Combinations </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 9 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R10.htm </HtmlFileName>
<LongName> 009 - Disclosure - Note 4 - Fair Value Measurements </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-4-fair-value-measurements </Role>
<ShortName> Note 4 - Fair Value Measurements </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 10 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R11.htm </HtmlFileName>
<LongName> 010 - Disclosure - Note 5 - Inventories </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-5-inventories </Role>
<ShortName> Note 5 - Inventories </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 11 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R12.htm </HtmlFileName>
<LongName> 011 - Disclosure - Note 6 - Property and Equipment </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-6-property-and-equipment- </Role>
<ShortName> Note 6 - Property and Equipment </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 12 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R13.htm </HtmlFileName>
<LongName> 012 - Disclosure - Note 7 - Acquired Intangible Assets, Net </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-7-acquired-intangible-assets-net </Role>
<ShortName> Note 7 - Acquired Intangible Assets, Net </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 13 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R14.htm </HtmlFileName>
<LongName> 013 - Disclosure - Note 8 - Goodwill </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-8-goodwill </Role>
<ShortName> Note 8 - Goodwill </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 14 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R15.htm </HtmlFileName>
<LongName> 014 - Disclosure - Note 9 - Leases </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-9-leases </Role>
<ShortName> Note 9 - Leases </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 15 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R16.htm </HtmlFileName>
<LongName> 015 - Disclosure - Note 10 - Accrued Expenses </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-10-accrued-expenses </Role>
<ShortName> Note 10 - Accrued Expenses </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 16 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R17.htm </HtmlFileName>
<LongName> 016 - Disclosure - Note 11 - Revolving Credit Agreement </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-11-revolving-credit-agreement </Role>
<ShortName> Note 11 - Revolving Credit Agreement </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 17 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R18.htm </HtmlFileName>
<LongName> 017 - Disclosure - Note 12 - Commitments and Contingencies </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-12-commitments-and-contingencies </Role>
<ShortName> Note 12 - Commitments and Contingencies </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 18 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R19.htm </HtmlFileName>
<LongName> 018 - Disclosure - Note 13 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-13-revenue-by-product-group-by-significant-customer-and-by-geographic-location-geographic-information </Role>
<ShortName> Note 13 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 19 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R20.htm </HtmlFileName>
<LongName> 019 - Disclosure - Note 14 - Equity Incentive Plan </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-14-equity-incentive-plan </Role>
<ShortName> Note 14 - Equity Incentive Plan </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 20 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R21.htm </HtmlFileName>
<LongName> 020 - Disclosure - Note 15 - Employee Benefit Plan </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-15-employee-benefit-plan- </Role>
<ShortName> Note 15 - Employee Benefit Plan </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 21 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R22.htm </HtmlFileName>
<LongName> 021 - Disclosure - Note 16 - Accelerated Share Repurchases </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-16-accelerated-share-repurchases </Role>
<ShortName> Note 16 - Accelerated Share Repurchases </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 22 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R23.htm </HtmlFileName>
<LongName> 022 - Disclosure - Note 17 - Income Taxes </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-17-income-taxes </Role>
<ShortName> Note 17 - Income Taxes </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 23 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R24.htm </HtmlFileName>
<LongName> 023 - Disclosure - Note 18 - Earnings Per Share ("EPS") </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-18-earnings-per-share-eps </Role>
<ShortName> Note 18 - Earnings Per Share ("EPS") </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 24 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R25.htm </HtmlFileName>
<LongName> 024 - Disclosure - Note 19 - Quarterly Financial Data (Unaudited) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-19-quarterly-financial-data-unaudited- </Role>
<ShortName> Note 19 - Quarterly Financial Data (Unaudited) </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 25 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R26.htm </HtmlFileName>
<LongName> 025 - Disclosure - Significant Accounting Policies (Policies) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-significant-accounting-policies-policies </Role>
<ShortName> Significant Accounting Policies (Policies) </ShortName>
<MenuCategory> Policies </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-2-summary-of-significant-accounting-policies </ParentRole>
<Position> 26 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R27.htm </HtmlFileName>
<LongName> 026 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-2-summary-of-significant-accounting-policies-tables </Role>
<ShortName> Note 2 - Summary of Significant Accounting Policies (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-2-summary-of-significant-accounting-policies </ParentRole>
<Position> 27 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R28.htm </HtmlFileName>
<LongName> 027 - Disclosure - Note 3 - Business Combinations (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-3-business-combinations-tables </Role>
<ShortName> Note 3 - Business Combinations (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-3-business-combinations </ParentRole>
<Position> 28 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R29.htm </HtmlFileName>
<LongName> 028 - Disclosure - Note 4 - Fair Value Measurements (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-4-fair-value-measurements-tables </Role>
<ShortName> Note 4 - Fair Value Measurements (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-4-fair-value-measurements </ParentRole>
<Position> 29 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R30.htm </HtmlFileName>
<LongName> 029 - Disclosure - Note 5 - Inventories (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-5-inventories-tables </Role>
<ShortName> Note 5 - Inventories (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-5-inventories </ParentRole>
<Position> 30 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R31.htm </HtmlFileName>
<LongName> 030 - Disclosure - Note 6 - Property and Equipment (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-6-property-and-equipment-tables </Role>
<ShortName> Note 6 - Property and Equipment (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-6-property-and-equipment- </ParentRole>
<Position> 31 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R32.htm </HtmlFileName>
<LongName> 031 - Disclosure - Note 7 - Acquired Intangible Assets, Net (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-7-acquired-intangible-assets-net-tables </Role>
<ShortName> Note 7 - Acquired Intangible Assets, Net (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-7-acquired-intangible-assets-net </ParentRole>
<Position> 32 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R33.htm </HtmlFileName>
<LongName> 032 - Disclosure - Note 8 - Goodwill (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-8-goodwill-tables </Role>
<ShortName> Note 8 - Goodwill (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-8-goodwill </ParentRole>
<Position> 33 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R34.htm </HtmlFileName>
<LongName> 033 - Disclosure - Note 9 - Leases (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-9-leases-tables </Role>
<ShortName> Note 9 - Leases (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-9-leases </ParentRole>
<Position> 34 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R35.htm </HtmlFileName>
<LongName> 034 - Disclosure - Note 10 - Accrued Expenses (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-10-accrued-expenses-tables </Role>
<ShortName> Note 10 - Accrued Expenses (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-10-accrued-expenses </ParentRole>
<Position> 35 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R36.htm </HtmlFileName>
<LongName> 035 - Disclosure - Note 13 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-13-revenue-by-product-group-by-significant-customer-and-by-geographic-location-geographic-information-tables </Role>
<ShortName> Note 13 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-13-revenue-by-product-group-by-significant-customer-and-by-geographic-location-geographic-information </ParentRole>
<Position> 36 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R37.htm </HtmlFileName>
<LongName> 036 - Disclosure - Note 14 - Equity Incentive Plan (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-14-equity-incentive-plan-tables </Role>
<ShortName> Note 14 - Equity Incentive Plan (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-14-equity-incentive-plan </ParentRole>
<Position> 37 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R38.htm </HtmlFileName>
<LongName> 037 - Disclosure - Note 17 - Income Taxes (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-17-income-taxes-tables </Role>
<ShortName> Note 17 - Income Taxes (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-17-income-taxes </ParentRole>
<Position> 38 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R39.htm </HtmlFileName>
<LongName> 038 - Disclosure - Note 18 - Earnings Per Share ("EPS") (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-18-earnings-per-share-eps-tables </Role>
<ShortName> Note 18 - Earnings Per Share ("EPS") (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-18-earnings-per-share-eps </ParentRole>
<Position> 39 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R40.htm </HtmlFileName>
<LongName> 039 - Disclosure - Note 19 - Quarterly Financial Data (Unaudited) (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-19-quarterly-financial-data-unaudited-tables </Role>
<ShortName> Note 19 - Quarterly Financial Data (Unaudited) (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-19-quarterly-financial-data-unaudited- </ParentRole>
<Position> 40 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R41.htm </HtmlFileName>
<LongName> 040 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual </Role>
<ShortName> Note 2 - Summary of Significant Accounting Policies (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-2-summary-of-significant-accounting-policies-tables </ParentRole>
<Position> 41 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R42.htm </HtmlFileName>
<LongName> 041 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details </Role>
<ShortName> Note 2 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 42 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R43.htm </HtmlFileName>
<LongName> 042 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details </Role>
<ShortName> Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 43 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R44.htm </HtmlFileName>
<LongName> 043 - Disclosure - Note 3 - Business Combinations (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-3-business-combinations-details-textual </Role>
<ShortName> Note 3 - Business Combinations (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-3-business-combinations-tables </ParentRole>
<Position> 44 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R45.htm </HtmlFileName>
<LongName> 044 - Disclosure - Note 3 - Business Combinations - Consideration Transferred (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-3-business-combinations-consideration-transferred-details </Role>
<ShortName> Note 3 - Business Combinations - Consideration Transferred (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 45 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R46.htm </HtmlFileName>
<LongName> 045 - Disclosure - Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details </Role>
<ShortName> Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 46 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R47.htm </HtmlFileName>
<LongName> 046 - Disclosure - Note 3 - Business Combinations - Intangible Assets Acquired (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-3-business-combinations-intangible-assets-acquired-details </Role>
<ShortName> Note 3 - Business Combinations - Intangible Assets Acquired (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 47 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R48.htm </HtmlFileName>
<LongName> 047 - Disclosure - Note 3 - Business Combinations - Pro Forma Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-3-business-combinations-pro-forma-information-details </Role>
<ShortName> Note 3 - Business Combinations - Pro Forma Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 48 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R49.htm </HtmlFileName>
<LongName> 048 - Disclosure - Note 4 - Fair Value Measurements (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-4-fair-value-measurements-details-textual </Role>
<ShortName> Note 4 - Fair Value Measurements (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-4-fair-value-measurements-tables </ParentRole>
<Position> 49 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R50.htm </HtmlFileName>
<LongName> 049 - Disclosure - Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details </Role>
<ShortName> Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 50 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R51.htm </HtmlFileName>
<LongName> 050 - Disclosure - Note 4 - Fair Value Measurements - Contingent Consideration (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-4-fair-value-measurements-contingent-consideration-details </Role>
<ShortName> Note 4 - Fair Value Measurements - Contingent Consideration (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 51 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R52.htm </HtmlFileName>
<LongName> 051 - Disclosure - Note 5 - Inventories (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-5-inventories-details-textual </Role>
<ShortName> Note 5 - Inventories (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-5-inventories-tables </ParentRole>
<Position> 52 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R53.htm </HtmlFileName>
<LongName> 052 - Disclosure - Note 5 - Inventories - Summary of Inventories (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-5-inventories-summary-of-inventories-details </Role>
<ShortName> Note 5 - Inventories - Summary of Inventories (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 53 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R54.htm </HtmlFileName>
<LongName> 053 - Disclosure - Note 6 - Property and Equipment (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-6-property-and-equipment-details-textual </Role>
<ShortName> Note 6 - Property and Equipment (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-6-property-and-equipment-tables </ParentRole>
<Position> 54 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R55.htm </HtmlFileName>
<LongName> 054 - Disclosure - Note 6 - Property and Equipment - Property and Equipment at Cost (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details </Role>
<ShortName> Note 6 - Property and Equipment - Property and Equipment at Cost (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 55 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R56.htm </HtmlFileName>
<LongName> 055 - Disclosure - Note 7 - Acquired Intangible Assets, Net (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-7-acquired-intangible-assets-net-details-textual </Role>
<ShortName> Note 7 - Acquired Intangible Assets, Net (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-7-acquired-intangible-assets-net-tables </ParentRole>
<Position> 56 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R57.htm </HtmlFileName>
<LongName> 056 - Disclosure - Note 7 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details </Role>
<ShortName> Note 7 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 57 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R58.htm </HtmlFileName>
<LongName> 057 - Disclosure - Note 8 - Goodwill (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-8-goodwill-details-textual </Role>
<ShortName> Note 8 - Goodwill (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-8-goodwill-tables </ParentRole>
<Position> 58 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R59.htm </HtmlFileName>
<LongName> 058 - Disclosure - Note 8 - Goodwill - Changes in the Carrying Value of Goodwill (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-8-goodwill-changes-in-the-carrying-value-of-goodwill-details </Role>
<ShortName> Note 8 - Goodwill - Changes in the Carrying Value of Goodwill (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 59 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R60.htm </HtmlFileName>
<LongName> 059 - Disclosure - Note 9 - Leases (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-9-leases-details-textual </Role>
<ShortName> Note 9 - Leases (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-9-leases-tables </ParentRole>
<Position> 60 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R61.htm </HtmlFileName>
<LongName> 060 - Disclosure - Note 9 - Leases - Lease Expense and Other Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-9-leases-lease-expense-and-other-information-details </Role>
<ShortName> Note 9 - Leases - Lease Expense and Other Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 61 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R62.htm </HtmlFileName>
<LongName> 061 - Disclosure - Note 9 - Leases - Future Minimum Rental Payments for Operating Leases (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-9-leases-future-minimum-rental-payments-for-operating-leases-details </Role>
<ShortName> Note 9 - Leases - Future Minimum Rental Payments for Operating Leases (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 62 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R63.htm </HtmlFileName>
<LongName> 062 - Disclosure - Note 10 - Accrued Expenses - Summary of Accrued Expenses (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-10-accrued-expenses-summary-of-accrued-expenses-details </Role>
<ShortName> Note 10 - Accrued Expenses - Summary of Accrued Expenses (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 63 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R64.htm </HtmlFileName>
<LongName> 063 - Disclosure - Note 11 - Revolving Credit Agreement (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-11-revolving-credit-agreement-details-textual </Role>
<ShortName> Note 11 - Revolving Credit Agreement (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-11-revolving-credit-agreement </ParentRole>
<Position> 64 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R65.htm </HtmlFileName>
<LongName> 064 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-12-commitments-and-contingencies-details-textual </Role>
<ShortName> Note 12 - Commitments and Contingencies (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-12-commitments-and-contingencies </ParentRole>
<Position> 65 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R66.htm </HtmlFileName>
<LongName> 065 - Disclosure - Note 13 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-13-revenue-by-product-group-by-significant-customer-and-by-geographic-location-geographic-information-details-textual </Role>
<ShortName> Note 13 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-13-revenue-by-product-group-by-significant-customer-and-by-geographic-location-geographic-information-tables </ParentRole>
<Position> 66 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R67.htm </HtmlFileName>
<LongName> 066 - Disclosure - Note 13 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information - Product Revenue by Product Group (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-13-revenue-by-product-group-by-significant-customer-and-by-geographic-location-geographic-information-product-revenue-by-product-group-details </Role>
<ShortName> Note 13 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information - Product Revenue by Product Group (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 67 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R68.htm </HtmlFileName>
<LongName> 067 - Disclosure - Note 13 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information - Total Revenue by Geographic Location (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-13-revenue-by-product-group-by-significant-customer-and-by-geographic-location-geographic-information-total-revenue-by-geographic-location-details </Role>
<ShortName> Note 13 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information - Total Revenue by Geographic Location (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 68 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R69.htm </HtmlFileName>
<LongName> 068 - Disclosure - Note 13 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information - Net Tangible Long-lived Assets by Principal Geographic Areas (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-13-revenue-by-product-group-by-significant-customer-and-by-geographic-location-geographic-information-net-tangible-longlived-assets-by-principal-geographic-areas-details </Role>
<ShortName> Note 13 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information - Net Tangible Long-lived Assets by Principal Geographic Areas (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 69 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R70.htm </HtmlFileName>
<LongName> 069 - Disclosure - Note 14 - Equity Incentive Plan (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-14-equity-incentive-plan-details-textual </Role>
<ShortName> Note 14 - Equity Incentive Plan (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-14-equity-incentive-plan-tables </ParentRole>
<Position> 70 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R71.htm </HtmlFileName>
<LongName> 070 - Disclosure - Note 14 - Equity Incentive Plan - Granted and Exercised Stock-based Compensation Awards (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-14-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details </Role>
<ShortName> Note 14 - Equity Incentive Plan - Granted and Exercised Stock-based Compensation Awards (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 71 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R72.htm </HtmlFileName>
<LongName> 071 - Disclosure - Note 14 - Equity Incentive Plan - Stock Options and SAR's Activity (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-14-equity-incentive-plan-stock-options-and-sars-activity-details </Role>
<ShortName> Note 14 - Equity Incentive Plan - Stock Options and SAR's Activity (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 72 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R73.htm </HtmlFileName>
<LongName> 072 - Disclosure - Note 14 - Equity Incentive Plan - Summary of Exercisable Options and SAR's (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-14-equity-incentive-plan-summary-of-exercisable-options-and-sars-details </Role>
<ShortName> Note 14 - Equity Incentive Plan - Summary of Exercisable Options and SAR's (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 73 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R74.htm </HtmlFileName>
<LongName> 073 - Disclosure - Note 14 - Equity Incentive Plan - Restricted Stock Activity (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details </Role>
<ShortName> Note 14 - Equity Incentive Plan - Restricted Stock Activity (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 74 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R75.htm </HtmlFileName>
<LongName> 074 - Disclosure - Note 14 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-14-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details </Role>
<ShortName> Note 14 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 75 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R76.htm </HtmlFileName>
<LongName> 075 - Disclosure - Note 14 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-14-equity-incentive-plan-total-stockbased-compensation-expense-details </Role>
<ShortName> Note 14 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 76 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R77.htm </HtmlFileName>
<LongName> 076 - Disclosure - Note 15 - Employee Benefit Plan (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-15-employee-benefit-plan-details-textual </Role>
<ShortName> Note 15 - Employee Benefit Plan (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-15-employee-benefit-plan- </ParentRole>
<Position> 77 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R78.htm </HtmlFileName>
<LongName> 077 - Disclosure - Note 16 - Accelerated Share Repurchases (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-16-accelerated-share-repurchases-details-textual </Role>
<ShortName> Note 16 - Accelerated Share Repurchases (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-16-accelerated-share-repurchases </ParentRole>
<Position> 78 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R79.htm </HtmlFileName>
<LongName> 078 - Disclosure - Note 17 - Income Taxes (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-17-income-taxes-details-textual </Role>
<ShortName> Note 17 - Income Taxes (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-17-income-taxes-tables </ParentRole>
<Position> 79 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R80.htm </HtmlFileName>
<LongName> 079 - Disclosure - Note 17 - Income Taxes - Components of Income Before Taxes and Provision for (Benefit from) Income Taxes (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-17-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details </Role>
<ShortName> Note 17 - Income Taxes - Components of Income Before Taxes and Provision for (Benefit from) Income Taxes (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 80 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R81.htm </HtmlFileName>
<LongName> 080 - Disclosure - Note 17 - Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-17-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details </Role>
<ShortName> Note 17 - Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 81 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R82.htm </HtmlFileName>
<LongName> 081 - Disclosure - Note 17 - Income Taxes - Reconciliation Between U.S. Federal Statutory Rate and Effective Rate (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-17-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details </Role>
<ShortName> Note 17 - Income Taxes - Reconciliation Between U.S. Federal Statutory Rate and Effective Rate (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 82 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R83.htm </HtmlFileName>
<LongName> 082 - Disclosure - Note 18 - Earnings Per Share ("EPS") (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-18-earnings-per-share-eps-details-textual </Role>
<ShortName> Note 18 - Earnings Per Share ("EPS") (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-18-earnings-per-share-eps-tables </ParentRole>
<Position> 83 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R84.htm </HtmlFileName>
<LongName> 083 - Disclosure - Note 18 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-18-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details </Role>
<ShortName> Note 18 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-18-earnings-per-share-eps-tables </ParentRole>
<Position> 84 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R85.htm </HtmlFileName>
<LongName> 084 - Disclosure - Note 19 - Quarterly Financial Data (Unaudited) (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-19-quarterly-financial-data-unaudited-details-textual </Role>
<ShortName> Note 19 - Quarterly Financial Data (Unaudited) (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-19-quarterly-financial-data-unaudited-tables </ParentRole>
<Position> 85 </Position>
</Report>
<Report instance="anik20201231_10k.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R86.htm </HtmlFileName>
<LongName> 085 - Disclosure - Note 19 - Quarterly Financial Data (Unaudited) - Quarterly Financial Data (Unaudited) (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.anikatherapeutics.com/20201231/role/statement-note-19-quarterly-financial-data-unaudited-quarterly-financial-data-unaudited-details </Role>
<ShortName> Note 19 - Quarterly Financial Data (Unaudited) - Quarterly Financial Data (Unaudited) (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.anikatherapeutics.com/20201231/role/statement-note-19-quarterly-financial-data-unaudited-tables </ParentRole>
<Position> 86 </Position>
</Report>
<Report>
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<LongName> All Reports </LongName>
<ReportType> Book </ReportType>
<ShortName> All Reports </ShortName>
</Report>
</MyReports>
<InputFiles>
<File doctype="10-K" original="anik20201231_10k.htm"> anik20201231_10k.htm </File>
<File> anik-20201231.xsd </File>
<File> anik-20201231_cal.xml </File>
<File> anik-20201231_def.xml </File>
<File> anik-20201231_lab.xml </File>
<File> anik-20201231_pre.xml </File>
<File> ex_231248.htm </File>
<File> ex_231249.htm </File>
<File> ex_231250.htm </File>
<File> ex_231421.htm </File>
<File> ex_231631.htm </File>
<File> ex_231632.htm </File>
<File> ex_231633.htm </File>
<File> ex_231634.htm </File>
</InputFiles>
<SupplementalFiles>
<File> anik20201231_10kimg001.gif </File>
</SupplementalFiles>
<BaseTaxonomies>
<BaseTaxonomy> http://fasb.org/us-gaap/2020-01-31 </BaseTaxonomy>
<BaseTaxonomy> http://fasb.org/srt/2020-01-31 </BaseTaxonomy>
<BaseTaxonomy> http://xbrl.sec.gov/country/2020-01-31 </BaseTaxonomy>
<BaseTaxonomy> http://xbrl.sec.gov/dei/2019-01-31 </BaseTaxonomy>
</BaseTaxonomies>
<HasPresentationLinkbase> true </HasPresentationLinkbase>
<HasCalculationLinkbase> true </HasCalculationLinkbase>
</FilingSummary>

5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/15/24  Anika Therapeutics, Inc.          10-K       12/31/23   90:9.1M                                   Globenewswire Inc./FA
 3/16/23  Anika Therapeutics, Inc.          10-K       12/31/22   97:10M                                    Globenewswire Inc./FA
 3/11/22  Anika Therapeutics, Inc.          10-K       12/31/21  105:25M                                    Globenewswire Inc./FA
 5/07/21  Anika Therapeutics, Inc.          10-Q        3/31/21   67:5.1M                                   Globenewswire Inc./FA
 4/26/21  Anika Therapeutics, Inc.          10-K/A     12/31/20  100:10M                                    Globenewswire Inc./FA

32 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/05/20  Anika Therapeutics, Inc.          8-K:5,7,9   8/05/20    3:95K                                    Globenewswire Inc./FA
 6/18/20  Anika Therapeutics, Inc.          8-K:5,9     6/16/20    2:194K                                   Globenewswire Inc./FA
 5/22/20  Anika Therapeutics, Inc.          10-Q        3/31/20   77:4.8M                                   Globenewswire Inc./FA
 4/29/20  Anika Therapeutics, Inc.          8-K:1,5,7,9 4/23/20    3:147K                                   Globenewswire Inc./FA
 3/06/20  Anika Therapeutics, Inc.          10-K       12/31/19   98:6.4M                                   Globenewswire Inc./FA
 3/02/20  Anika Therapeutics, Inc.          8-K:5,9     2/25/20    2:53K                                    Globenewswire Inc./FA
 1/07/20  Anika Therapeutics, Inc.          8-K:1,9     1/04/20    3:1.2M                                   Globenewswire Inc./FA
 7/26/19  Anika Therapeutics, Inc.          10-Q        6/30/19   68:3.4M                                   Globenewswire Inc./FA
 7/10/19  Anika Therapeutics, Inc.          8-K:5       7/05/19    3:131K                                   Globenewswire Inc./FA
 6/20/19  Anika Therapeutics, Inc.          8-K:5,9     6/18/19    2:185K                                   Globenewswire Inc./FA
 4/12/19  Anika Therapeutics, Inc.          8-K:5,9     4/09/19    5:230K                                   Globenewswire Inc./FA
 7/31/18  Anika Therapeutics, Inc.          10-Q        6/30/18   62:2.9M                                   Globenewswire Inc./FA
 6/06/18  Anika Therapeutics, Inc.          8-K:5,8,9   5/31/18    4:323K                                   Globenewswire Inc./FA
 3/08/18  Anika Therapeutics, Inc.          8-K:5,8,9   3/02/18    4:141K                                   Globenewswire Inc./FA
10/27/17  Anika Therapeutics, Inc.          10-Q        9/30/17   66:4.1M                                   Globenewswire Inc./FA
 7/27/17  Anika Therapeutics, Inc.          8-K:5,7,9   7/27/17    3:116K                                   Business Wire/FA
 6/19/17  Anika Therapeutics, Inc.          8-K:5,9     6/13/17    6:320K                                   Globenewswire Inc./FA
 2/24/17  Anika Therapeutics, Inc.          10-K       12/31/16   86:5.9M                                   Globenewswire Inc./FA
 5/03/16  Anika Therapeutics, Inc.          10-Q        3/31/16   65:2.6M                                   Globenewswire Inc./FA
10/14/15  Anika Therapeutics, Inc.          8-K:1,9    10/09/15    2:252K                                   Business Wire/FA
 5/05/14  Anika Therapeutics, Inc.          10-Q        3/31/14   61:3.5M                                   Globenewswire Inc./FA
12/22/11  Anika Therapeutics, Inc.          8-K:1,9    12/21/11    3:832K                                   Business Wire/FA
 6/10/11  Anika Therapeutics, Inc.          8-K:5,9     6/07/11    2:108K                                   Business Wire/FA
 3/16/11  Anika Therapeutics, Inc.          10-K       12/31/10   10:2M                                     Business Wire/FA
 1/06/10  Anika Therapeutics, Inc.          8-K:1,2,3,912/30/09    7:1.4M                                   Business Wire/FA
 9/14/09  Anika Therapeutics, Inc.          8-K:5       9/10/09    3:108K                                   Business Wire/FA
10/22/08  Anika Therapeutics, Inc.          8-K:5      10/17/08    3:249K                                   Business Wire/FA
 3/12/08  Anika Therapeutics, Inc.          10-K       12/31/07    8:784K                                   Toppan Merrill-FA
 2/06/08  Anika Therapeutics, Inc.          8-K:1,5,9   1/31/08    4:794K                                   Toppan Merrill/FA
 1/10/07  Anika Therapeutics, Inc.          8-K:1,2,9   1/04/07    2:489K                                   Toppan Merrill/FA
10/05/04  Anika Therapeutics, Inc.          8-K:1,5,9   9/29/04    6:201K                                   Toppan Merrill/FA
 3/30/04  Anika Therapeutics, Inc.          10-K       12/31/03    8:741K                                   Toppan Merrill-FA
↑Top
Filing Submission 0001171843-21-001573   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Thu., May 2, 11:25:43.3pm ET